Managing renal transplant ischemia reperfusion injury: Novel therapies in the pipeline

Clinical Transplantation

Volumn 27, Issue 4, 2013, Pages 484-491

  Powell, Jaclyn T ^a   Tsapepas, Demetra S ^a   Martin, Spencer T ^a   Hardy, Mark A ^b   Ratner, Lloyd E ^b  

^a NewYork Presbyterian Hospital   (United States)

^b College of Physicians and Surgeons ^*  (United States)

Author keywords

Delayed graft function; Drug development; Ischemia reperfusion injury; Organ protection and preservation; Renal transplantation

Indexed keywords

BLOOD CLOTTING INHIBITOR; CD3 ANTIGEN; CREATININE; DIANNEXIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GAMMA INTERFERON; HOMODIMER; HYBRID PROTEIN; I5NP; IMMUNOGLOBULIN G1; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6; INTERLEUKIN 8; LIPOCORTIN 5; MONOCYTE CHEMOTACTIC PROTEIN 1; P SELECTIN GLYCOPROTEIN LIGAND 1; PADGEM PROTEIN; PHOSPHATIDYLSERINE; PROTEIN P53; RECOMBINANT PROTEIN; SMALL INTERFERING RNA; SUPEROXIDE; SUPEROXIDE DISMUTASE; THYMOCYTE ANTIBODY; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; YSPSL;

ACUTE GRAFT REJECTION; ACUTE KIDNEY TUBULE NECROSIS; ANTICOAGULATION; COLD ISCHEMIA; CREATININE BLOOD LEVEL; DELAYED GRAFT FUNCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; ENDOTHELIUM CELL; GLOMERULUS FILTRATION; GLOMERULUS FILTRATION RATE; GRAFT SURVIVAL; HEALTH CARE COST; HOSPITALIZATION; HUMAN; IMMUNOGENICITY; KIDNEY ALLOGRAFT; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY PROXIMAL TUBULE; KIDNEY TRANSPLANTATION; LENGTH OF STAY; MULTICENTER STUDY (TOPIC); NEUTROPHIL; NONHUMAN; PEROPERATIVE CARE; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL REPLACEMENT THERAPY; REPERFUSION; REPERFUSION INJURY; REVIEW; RNA INTERFERENCE; SYSTEMATIC REVIEW; URINE VOLUME;

DELAYED GRAFT FUNCTION; DRUG DEVELOPMENT; ISCHEMIA/REPERFUSION INJURY; ORGAN PROTECTION AND PRESERVATION; RENAL TRANSPLANTATION;

DISEASE MANAGEMENT; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; REPERFUSION INJURY;

EID: 84881547447     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12121     Document Type: Review

References (39)

1. Cecka M. Clinical outcome of renal transplantation. Factors influencing patient and graft survival. Surg Clin North Am 1998: 78: 133.
2. Perico N, Cattaneo D, Sayegh MH, Remuzzi G. Delayed graft function in kidney transplantation. Lancet 2004: 364: 1814.
3. Eltzschig HK, Eckle T. Ischemia and reperfusion-from mechanism to translation. Nat Med 2011: 17: 1391.
4. Bonventre JV. Mediators of ischemic renal injury. Annu Rev Med 1988: 39: 531.
5. Lutz J, Thurmel K, Heemann U. Anti-inflammatory treatment strategies for ischemia/reperfusion injury in transplantation. J Inflamm (Lond) 2010: 7: 27.
6. Jang HR, Ko GJ, Wasowska BA, Rabb H. The interaction between ischemia-reperfusion and immune responses in the kidney. J Mol Med (Berl) 2009: 87: 859.
7. Shackleton CR, Ettinger SL, McLoughlin MG, Scudamore CH, Miller RR, Keown PA. Effect of recovery from ischemic injury on class I and class II MHC antigen expression. Transplantation 1990: 49: 641.
8. SRTR. OPTN & SRTR Annual Data Report 2010. Am J Transplant 2012: 12(suppl 1): 9.
9. Land W, Schneeberger H, Schleibner S et al. The beneficial effect of human recombinant superoxide dismutase on acute and chronic rejection events in recipients of cadaveric renal transplants. Transplantation 1994: 57: 211.
10. Schneeberger H, Illner WD, Abendroth D et al. First clinical experiences with superoxide dismutase in kidney transplantation-results of a double-blind randomized study. Transplant Proc 1989: 21(1 Pt 2): 1245.
11. Chappell D, Beiras-Fernandez A, Hammer C, Thein E. In vivo visualization of the effect of polyclonal antithymocyte globulins on the microcirculation after ischemia/reperfusion in a primate model. Transplantation 2006: 81: 552.
12. Beiras-Fernandez A, Chappell D, Hammer C, Beiras A, Reichart B, Thein E. Impact of polyclonal anti-thymocyte globulins on the expression of adhesion and inflammation molecules after ischemia-reperfusion injury. Transpl Immunol 2009: 20: 224.
13. Goggins WC, Pascual MA, Powelson JA et al. A prospective, randomized, clinical trial of intraoperative versus postoperative Thymoglobulin in adult cadaveric renal transplant recipients. Transplantation 2003: 76: 798.
14. Ran S, Downes A, Thorpe PE. Increased exposure of anionic phospholipids on the surface of tumor blood vessels. Cancer Res 2002: 62: 6132.
15. Neidlinger NA, Hirvela ER, Skinner RA, Larkin SK, Harken AH, Kuypers FA. Postinjury serum secretory phospholipase A2 correlates with hypoxemia and clinical status at 72 hours. J Am Coll Surg 2005: 200: 173.
16. Moss SE, Morgan RO. The annexins. Genome Biol 2004: 5: 219.
17. Oling F, Bergsma-Schutter W, Brisson A. Trimers, dimers of trimers, and trimers of trimers are common building blocks of annexin a5 two-dimensional crystals. J Struct Biol 2001: 133: 55.
18. Wever KE, Wagener FA, Frielink C et al. Diannexin protects against renal ischemia reperfusion injury and targets phosphatidylserines in ischemic tissue. PLoS ONE 2011: 6: e24276.
19. Kuypers FA, Larkin SK, Emeis JJ, Allison AC. Interaction of an annexin V homodimer (Diannexin) with phosphatidylserine on cell surfaces and consequent antithrombotic activity. Thromb Haemost 2007: 97: 478.
20. Cooper M, Kapur S, Stratta R. Diannexin, a novel ischemia/reperfusion therapeutic agent, reduces delayed graft function (DGF) in renal transplant recipients from marginal donors (abstract #145). Am J Transplant 2010: 10(suppl 4): 37.
21. AstellasPharmaInc. A phase 2/3, double-blind, placebo-controlled, two-part study (part 1 open-label) to assess the safety, efficacy and pharmacokinetics of single intravenous doses of ASP8597 (Diannexin) in de novo kidney transplant recipients. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US), 2000. Available from: http://clinicaltrials.gov/ct2/show/NCT01442337 NLM Identifier: NCT01442337. [Accessed on February 1, 2012].
22. Gasser M, Waaga AM, Kist-Van Holthe JE et al. Normalization of brain death-induced injury to rat renal allografts by recombinant soluble P-selectin glycoprotein ligand. J Am Soc Nephrol 2002: 13: 1937.
23. McEver RP, Cummings RD. Role of PSGL-1 binding to selectins in leukocyte recruitment. J Clin Invest 1997: 100(11 Suppl): S97.
24. Amersi F, Farmer DG, Shaw GD et al. P-selectin glycoprotein ligand-1 (rPSGL-Ig)-mediated blockade of CD62 selectin molecules protects rat steatotic liver grafts from ischemia/reperfusion injury. Am J Transplant 2002: 2: 600.
25. Farmer DG, Shen XD, Amersi F et al. CD62 blockade with P-Selectin glycoprotein ligand-immunoglobulin fusion protein reduces ischemia-reperfusion injury after rat intestinal transplantation. Transplantation 2005: 79: 44.
26. Y'sTherapeutics I. Controlled, randomized, prospective, double-blind, multicenter, phase I/II, dose-escalation study of the safety, PK, and efficacy of YSPSL for prevention of delayed graft function in patients undergoing cadaveric kidney transplantation. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US), 2000. Available from: http://clinicaltrials.gov/ct2/show/NCT00298181?term=NCT00298181 NLM Identifier: NCT00298181. [Accessed on February 1, 2012].
27. Gaber AO, Mulgaonkar S, Kahan BD et al. YSPSL (rPSGL-Ig) for improvement of early renal allograft function: a double-blind, placebo-controlled, multi-center Phase IIa study. Clin Transplant 2011: 25: 523.
28. Cheadle C, Watkins T, Ehrlich E et al. Effects of anti-adhesive therapy on kidney biomarkers of ischemia reperfusion injury in human deceased donor kidney allografts. Clin Transplant 2011: 25: 766.
29. Kelly KJ, Plotkin Z, Vulgamott SL, Dagher PC. P53 mediates the apoptotic response to GTP depletion after renal ischemia-reperfusion: protective role of a p53 inhibitor. J Am Soc Nephrol 2003: 14: 128.
30. Moll UM, Zaika A. Nuclear and mitochondrial apoptotic pathways of p53. FEBS Lett 2001: 493: 65.
31. Martinez-Mier G, Toledo-Pereyra LH, Bussell S et al. Nitric oxide diminishes apoptosis and p53 gene expression after renal ischemia and reperfusion injury. Transplantation 2000: 70: 1431.
32. Vincenti F, Kirk AD. What's next in the pipeline. Am J Transplant 2008: 8: 1972.
33. Molitoris BA, Dagher PC, Sandoval RM et al. siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury. J Am Soc Nephrol 2009: 20: 1754.
34. QuarkPharmaceuticals. Controlled, randomized, prospective, double-blind, multicenter, phase I/II, dose-escalation study of the safety, PK, and clinical activity of I5NP for prophylaxis of delayed graft function in patients undergoing deceased donor kidney transplantation. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US), 2000. Available from:http://clinicaltrials.gov/ct2/show/NCT00802347 NLM Identifier: NCT00802347. [Accessed on February 1 2012].
35. Feldman HI, Gayner R, Berlin JA et al. Delayed function reduces renal allograft survival independent of acute rejection. Nephrol Dial Transplant 1996: 11: 1306.
36. Shoskes DA, Cecka JM. Deleterious effects of delayed graft function in cadaveric renal transplant recipients independent of acute rejection. Transplantation 1998: 66: 1697.
37. Almond PS, Matas AJ, Canafax DM. Fixed-rate reimbursement fails to cover costs for patients with delayed graft function. Pharmacotherapy 1991: 11: 126S.
38. Gjertson DW. Impact of delayed graft function and acute rejection on kidney graft survival. Clin Transpl 2000: ????: 467.
39. Selzner N, Boehnert M, Selzner M. Preconditioning, postconditioning, and remote conditioning in solid organ transplantation: basic mechanisms and translational applications. Transplant Rev (Orlando) 2012: 26: 115.